ImmunoPET: concept, design, and applications
W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
In vivo imaging with antibodies and engineered fragments
Antibodies have clearly demonstrated their utility as therapeutics, providing highly selective
and effective drugs to treat diseases in oncology, hematology, cardiology, immunology and …
and effective drugs to treat diseases in oncology, hematology, cardiology, immunology and …
Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy
Z Hu, R Li, X Cui, Z Chen - ACS Applied Materials & Interfaces, 2023 - ACS Publications
Colorectal cancer (CRC) is presently the third deadliest cancer in the world. This malignant
cancer usually precedes the progression of precancerous lesions, and it is challenging to …
cancer usually precedes the progression of precancerous lesions, and it is challenging to …
ImmunoPET: antibody-based PET imaging in solid tumors
Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …
combining the high sensitivity of PET with the specific targeting ability of monoclonal …
Nanoparticles and radiotracers: advances toward radionanomedicine
In this study, we cover the convergence of radiochemistry for imaging and therapy with
advances in nanoparticle (NP) design for biomedical applications. We first explore NP …
advances in nanoparticle (NP) design for biomedical applications. We first explore NP …
Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer
NY Luo, RL Minne, JP Gallant… - Bioconjugate …, 2024 - ACS Publications
The Mesenchymal Epithelial Transition (MET) receptor tyrosine kinase is upregulated or
mutated in 5% of non-small-cell lung cancer (NSCLC) patients and overexpressed in …
mutated in 5% of non-small-cell lung cancer (NSCLC) patients and overexpressed in …
PET imaging of receptor tyrosine kinases in cancer
Overexpression and/or mutations of the receptor tyrosine kinase (RTK) subfamilies, such as
epidermal growth factor receptors (EGFR) and vascular endothelial growth factor receptors …
epidermal growth factor receptors (EGFR) and vascular endothelial growth factor receptors …
[HTML][HTML] Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts
A El-Sayed, W Bernhard, K Barreto, C Gonzalez… - Theranostics, 2018 - ncbi.nlm.nih.gov
In vivo imaging is influenced by the half-life, tissue penetration, biodistribution, and affinity of
the imaging probe. Immunoglobulin G (IgG) is composed of discrete domains with known …
the imaging probe. Immunoglobulin G (IgG) is composed of discrete domains with known …
Novel receptor tyrosine kinase pathway inhibitors for targeted radionuclide therapy of glioblastoma
J Bolcaen, S Nair, CHS Driver, TMG Boshomane… - Pharmaceuticals, 2021 - mdpi.com
Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate
and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is …
and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is …
Detection of colorectal cancer using a small molecular fluorescent probe targeted against c-Met
J Tao, Y Tu, P Liu, Y Tang, F Wang, Z Li, C Li, Y Li… - Talanta, 2021 - Elsevier
Colorectal cancer (CRC), a highly heterogeneous genetic disease, is currently the second
leading cause of cancer-related deaths worldwide. This malignant cancer is typically …
leading cause of cancer-related deaths worldwide. This malignant cancer is typically …